AZN Astrazeneca PLC

40.94
+0.51  (+1%)
Previous Close 40.43
Open 40.44
Price To Book 8.69
Market Cap 103750266562
Shares 2,534,202,896
Volume 5,956,284
Short Ratio 2.07
Av. Daily Volume 5,171,550

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b/2 preliminary data due 4Q 2019.
Tagrisso and G1T38
EGFR mutation-positive non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Tezepelumab - NAVIGATOR
Asthma
Expanded approval announced August 28, 2017.
Faslodex (fulvestrant)
Monotherapy for expanded use in women with HR+, HER2- advanced breast cancer
Pooled MACE safety data 1H 2019.
Roxadustat
Anaemia in Chronic Kidney Disease
Phase 3 data due 2020.
Farxiga (Dapa-CKD)
Chronic Kidney Disease
Phase 3 data met one of two primary endpoints - 3Q 2018.
Farxiga - DECLARE
Type-2 diabetes
Phase 1 trial - two patients have recorded complete responses.
MEDI0457
HPV-associated squamous cell carcinoma of the head & neck (SCCHN)
Phase 3 data released November 1, 2017 - primary endpoint not met.
Tralokinumab (STRATOS2)
Severe, uncontrolled asthma
Phase 3 data due 2020.
Farxiga (Dapa-HF)
Heart failure
Phase 3 data released May 30, 2018. Primary endpoint not met.
Benralizumab - TERRANOVA
COPD
Phase 3 data due 2020.
Roxadustat
Myelodysplastic syndromes (MDS)
Approval announced March 31, 2017.
Tagrisso
Epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Durvalumab (ADJUVANT)
Adjuvant Non-small cell lung cancer (NSCLC)
Phase 3 trial did not meet primary endpoint - May 10, 2017.
Tralokinumab (STRATOS1)
Severe, uncontrolled asthma
Phase 3 trial did not meet primary endpoint - noted July 26, 2018.
Selumetinib - ASTRA
Thyroid cancer
Phase 3 data due 2H 2019.
PT010
Chronic obstructive pulmonary disease (COPD)
FDA approval announced September 13, 2018.
Moxetumomab
Cancer - leukaemia
FDA Approval announced December 19, 2018.
Lynparza - SOLO 1
First-line ovarian cancer following platinum-based chemotherapy
Approval announced August 17, 2017.
Lynparza - SOLO 2
Second-line ovarian cancer
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). Approval announced January 12, 2018.
Lynparza
Breast cancer
Phase 3 data released July 27, 2017 - primary endpoint (PFS) not met. Overall survival data also did not meet primary endpoint - November 16, 2018.
Durvalumab +/- tremelimumab (MYSTIC)
Lung cancer
Phase 3 data due 2H 2019.
Durvalumab +/- tremelimumab (NEPTUNE)
Lung cancer
Phase 3 data 1H 2019.
Durvalumab +/- tremelimumab (KESTREL)
Head & neck cancer
Phase 3 data due 2H 2019.
Durvalumab +/- tremelimumab (DANUBE)
Bladder cancer
Phase 3 data released December 7, 2018 - primary endpoints not met.
Durvalumab +/- tremelimumab (EAGLE)
Head & neck cancer
Phase 3 data released April 24, 2018 - primary endpoints not met.
Durvalumab +/- tremelimumab (ARCTIC)
Non-small cell lung cancer (NSCLC)
Approval announced February 19, 2018.
Durvalumab (PACIFIC)
Lung cancer
Phase 3 Cardiovascular Outcome trial data released September 14, 2017 - primary efficacy objective of a superior reduction in MACE missed statistical significance (p=0.061).
Bydureon
Type 2 Diabetes
Phase 3 data due 1H 2019.
Brilinta (THEMIS)
Type 2 Diabetes
Phase 3 TULIP 1 data released August 31, 2018. Primary endpoint not met. TULIP 2 data are due estimate 1Q 2019.
Anifrolumab
Lupus
Priority Review announced August 2, 2017. Approval announced October 31, 2017.
Acalabrutinib
Relapsed or Refractory Mantle Cell Lymphoma
BLA acceptance announced December 9, 2017. PDUFA under priority review. Approval announced May 1, 2017.
Urothelial carcinoma - Bladder cancer
Bladder cancer
Second CRL issued March 17, 2017. Approval announced May 18, 2018.
Lokelma (ZS-9)
Hyperkalaemia
Approval announced February 28, 2017.
Saxagliptin and dapagliflozin
Type-2 diabetes
Approval announced November 14, 2017.
Benralizumab
Severe, uncontrolled asthma
Announced discontinuation of trial due to futility - June 12, 2018.
Lanabecestat (AZD3293) - AMARANTH
Early Alzheimer's disease
Phase 3 data released December 20, 2018 met primary and secondary endpoints.
Lynparza - SOLO 3
Third-line ovarian cancer
Phase 3 data due 1H 2019.
Lynparza
Pancreatic cancer
Phase 3 data due 2H 2019.
Imfinzi + tremelimumab (POSEIDON)
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2H 2019.
Imfinzi + tremelimumab (CASPIAN)
Small cell lung cancer (SCLC)
Phase 3 data due 2020.
Lynparza - OlympiA
HER2-negative breast cancer
Phase 3 trial did not meet primary endpoint - noted May 11, 2018.
Fasenra (benralizumab) - GALATHEA
Chronic obstructive pulmonary disease (COPD)
Phase 3 data due 2H 2019.
Lynparza
Castration-Resistant Prostate Cancer
Phase 3 data due 2H 2019.
Calquence
Chronic lymphocytic leukaemia
Phase 3 data due 2H 2019.
Lynparza + Avastin- PAOLA-1
First-line ovarian cancer
Phase 1b/2 data presented at ESMO 2018. 23% PR/CR.
Durvalumab Plus Danvatirsen
Refractory head and neck cancer
Phase 3 final OS data due 2H 2019.
Tagrisso - FLAURA
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Brilinta (THALES)
Acute ischaemic stroke
Phase 1a interim data due mid-2019.
ABI-H2158
Hepatitis B virus (HBV)
Phase 3 data due 2020.
Epanova
Hypertriglyceridaemia CVOT
Phase 3 data due 2019.
Fasenra
Nasal polyps
Phase 3 data due 2020.
Imfinzi
Neoadjuvant NSCLC

Latest News

  1. 2 Pharma Stocks in the Middle of an Oncology Sales Explosion
  2. Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why
  3. What Are Merck’s Key Growth Drivers for 2019?
  4. Strength Seen in AstraZeneca (AZN): Stock Soars 9.3%
  5. Why Marathon Oil, AstraZeneca, and Bloomin' Brands Jumped Today
  6. AstraZeneca Earnings Beat Views; Company Says It's 'Returned To Growth'
  7. FTSE 100 squeezes out gains; ConvaTec drags midcaps
  8. AstraZeneca Earnings: AZN Stock Zooms Higher on Q4 Beat
  9. European shares give up three-month highs after shock U.S. data
  10. European shares give up 3-month highs after shock U.S. data
  11. AstraZeneca retires MedImmune brand; Jallal leaves for new company
  12. Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise
  13. BMY vs. AZN: Which Stock Is the Better Value Option?
  14. Tanabe Research Labs Announce FDA Acceptance of its IND Application for TR1801-ADC (MT-8633), an ADC Targeting cMet Positive Solid Tumors
  15. AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales
  16. [$$] AstraZeneca Turns a Corner After a Decade of Struggles
  17. Brexit preparations have cost £40 million to £50 million: AstraZeneca CEO
  18. New cancer drugs, China give AstraZeneca welcome sales boost
  19. Astrazeneca: 4Q Earnings Snapshot
  20. AstraZeneca Surges as Oncology Sales Drive Q4 Earnings Beat, Solid 2019 Outlook